HYPOTHESIS: Microsurgical implantation of mouse merlin-deficient Schwann cells (MD-SC) into the cerebellopontine angle of immunodeficient rats will initiate tumor formation, hearing loss, and vestibular dysfunction. BACKGROUND: The progress in identifying effective drug therapies for treatment of Neurofibromatosis type II (NF2) is limited by the availability of animal models of VS that develop hearing loss and imbalance. METHODS: A microsurgical technique for implanting MD-SCs onto the cochleovestibular nerve of rats was developed. Ten Rowett Nude rats were implanted with either ∼10 MD-SCs expressing luciferase (N = 5) or vehicle (N = 5). Rats received bioluminescence imaging, auditory brainstem response testing, and were observed for head tilt every 2 weeks after surgery, for a total of 6 weeks. Tumors were harvested and processed with hematoxylin & eosin staining and immunohistochemistry was performed for S100. RESULTS: Rats implanted with MD-SCs developed significantly higher tumor bioluminescence measurements and hearing threshold shifts at multiple frequencies by the 4th and 6th weeks post-implantation, compared with control rats. Rats implanted with MD-SCs also developed gross tumor. The tumor volume was significantly greater than nerve volumes obtained from rats in the control group. All rats with tumors developed a head tilt, while control rats had no signs of vestibular dysfunction. Tumors demonstrated histological features of schwannoma and express S100. CONCLUSION: Using this microsurgical technique, this xenograft rat model of VS develops tumors involving the cochleovestibular nerve, shifts in hearing thresholds, and vestibular dysfunction. This animal model can be used to investigate tumor-mediated hearing loss and perform preclinical drug studies for NF2.
HYPOTHESIS: Microsurgical implantation of mousemerlin-deficient Schwann cells (MD-SC) into the cerebellopontine angle of immunodeficientrats will initiate tumor formation, hearing loss, and vestibular dysfunction. BACKGROUND: The progress in identifying effective drug therapies for treatment of Neurofibromatosis type II (NF2) is limited by the availability of animal models of VS that develop hearing loss and imbalance. METHODS: A microsurgical technique for implanting MD-SCs onto the cochleovestibular nerve of rats was developed. Ten Rowett Nude rats were implanted with either ∼10 MD-SCs expressing luciferase (N = 5) or vehicle (N = 5). Rats received bioluminescence imaging, auditory brainstem response testing, and were observed for head tilt every 2 weeks after surgery, for a total of 6 weeks. Tumors were harvested and processed with hematoxylin & eosin staining and immunohistochemistry was performed for S100. RESULTS:Rats implanted with MD-SCs developed significantly higher tumor bioluminescence measurements and hearing threshold shifts at multiple frequencies by the 4th and 6th weeks post-implantation, compared with control rats. Rats implanted with MD-SCs also developed gross tumor. The tumor volume was significantly greater than nerve volumes obtained from rats in the control group. All rats with tumors developed a head tilt, while control rats had no signs of vestibular dysfunction. Tumors demonstrated histological features of schwannoma and express S100. CONCLUSION: Using this microsurgical technique, this xenograft rat model of VS develops tumors involving the cochleovestibular nerve, shifts in hearing thresholds, and vestibular dysfunction. This animal model can be used to investigate tumor-mediated hearing loss and perform preclinical drug studies for NF2.
Authors: Daniel Jethanamest; Andrew M Rivera; Hongzhao Ji; Venkatakarthikeyan Chokkalingam; Fred F Telischi; Simon I Angeli Journal: Laryngoscope Date: 2015-02-03 Impact factor: 3.325
Authors: Scott R Plotkin; Vanessa L Merker; Chris Halpin; Dominique Jennings; Michael J McKenna; Gordon J Harris; Fred G Barker Journal: Otol Neurotol Date: 2012-08 Impact factor: 2.311
Authors: Abraham Jacob; Janet Oblinger; Matthew L Bush; Victoria Brendel; Griffin Santarelli; Abhik R Chaudhury; Samuel Kulp; Krista M D La Perle; Ching-Shih Chen; Long-Sheng Chang; D Bradley Welling Journal: Laryngoscope Date: 2011-11-22 Impact factor: 3.325
Authors: Jeffrey R Gehlhausen; Su-Jung Park; Ann E Hickox; Matthew Shew; Karl Staser; Steven D Rhodes; Keshav Menon; Jacquelyn D Lajiness; Muithi Mwanthi; Xianlin Yang; Jin Yuan; Paul Territo; Gary Hutchins; Grzegorz Nalepa; Feng-Chun Yang; Simon J Conway; Michael G Heinz; Anat Stemmer-Rachamimov; Charles W Yates; D Wade Clapp Journal: Hum Mol Genet Date: 2014-08-11 Impact factor: 6.150
Authors: Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen Journal: Neuro Oncol Date: 2012-07-27 Impact factor: 12.300
Authors: Torin P Thielhelm; Aida Nourbakhsh; Scott M Welford; Eric A Mellon; Olena Bracho; Michael E Ivan; Fred Telischi; Cristina Fernandez-Valle; Christine T Dinh Journal: Otolaryngol Head Neck Surg Date: 2022-03-01 Impact factor: 5.591
Authors: Enrique R Perez; Olena Bracho; Liliana Ein; Mikhaylo Szczupak; Paula V Monje; Cristina Fernandez-Valle; Abdulaziz Alshaiji; Michael Ivan; Jacques Morcos; Xue-Zhong Liu; Michael Hoffer; Adrien Eshraghi; Simon Angeli; Fred Telischi; Christine T Dinh Journal: Otol Neurotol Date: 2018-09 Impact factor: 2.311
Authors: Jessica E Sagers; Roberta L Beauchamp; Yanling Zhang; Sasa Vasilijic; Limeng Wu; Patrick DeSouza; Richard Seist; Wenjianlong Zhou; Lei Xu; Vijaya Ramesh; Konstantina M Stankovic Journal: Sci Rep Date: 2020-03-06 Impact factor: 4.379